FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 295 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... November 5, 2021 Immune interception represents an exciting opportunity to stop cancer in its... September 16, 2025 When Caregiving Takes a Toll May 28, 2021 Advanced MRI could help to differentiate aggressive and slower growing prostate... February 14, 2022 Load more HOT NEWS ‘Will cancer make me infertile?’ – That Cancer Conversation FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
